Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Obsidian Therapeutics, Inc (OBX) had Normalized Pre-Tax Income of $-100.61M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-100.61M |
|
-- |
|
-- |
|
$105.67M |
|
$-105.67M |
|
$5.06M |
|
$-100.61M |
|
|
Normalized Pre-Tax Income |
$-100.61M |
$-100.61M |
|
$-100.61M |
|
$-100.61M |
|
$-100.61M |
|
$-105.67M |
|
$-104.18M |
|
13.94M |
|
13.94M |
|
$-7.22 |
|
$-7.22 |
|
| Balance Sheet Financials | |
$81.52M |
|
$1.91M |
|
$7.06M |
|
$88.58M |
|
$15.36M |
|
-- |
|
$339.25M |
|
$354.62M |
|
$-266.04M |
|
$-266.04M |
|
$-266.04M |
|
13.94M |
|
| Cash Flow Statement Financials | |
$-90.39M |
|
$81.02M |
|
$0.02M |
|
$50.77M |
|
$41.41M |
|
$-9.36M |
|
$8.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.31 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-90.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
37.82% |
|
37.82% |
|
-113.58% |
|
37.82% |
|
$-19.08 |
|
$-6.49 |
|
$-6.49 |
|